Prostacyclin

(Redirected from PGI2)
Jump to: navigation, search
Prostacyclin-2D-skeletal.png
Prostacyclin
Systematic (IUPAC) name
5-[7-hydroxy-8- (3-hydroxyoct-1-enyl) -4-oxabicyclo[3.3.0]oct-3-ylidene] pentanoic acid
Identifiers
CAS number 35121-78-9
ATC code B01AC09
PubChem 114805
DrugBank APRD00949
Chemical data
Formula C20H32O5 
Mol. mass 352.465 g/mol
SMILES eMolecules & PubChem
Pharmacokinetic data
Bioavailability  ?
Metabolism  ?
Half life  ?
Excretion  ?
Therapeutic considerations
Pregnancy cat.

?

Legal status
Routes  ?

WikiDoc Resources for

Prostacyclin

Articles

Most recent articles on Prostacyclin

Most cited articles on Prostacyclin

Review articles on Prostacyclin

Articles on Prostacyclin in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Prostacyclin

Images of Prostacyclin

Photos of Prostacyclin

Podcasts & MP3s on Prostacyclin

Videos on Prostacyclin

Evidence Based Medicine

Cochrane Collaboration on Prostacyclin

Bandolier on Prostacyclin

TRIP on Prostacyclin

Clinical Trials

Ongoing Trials on Prostacyclin at Clinical Trials.gov

Trial results on Prostacyclin

Clinical Trials on Prostacyclin at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Prostacyclin

NICE Guidance on Prostacyclin

NHS PRODIGY Guidance

FDA on Prostacyclin

CDC on Prostacyclin

Books

Books on Prostacyclin

News

Prostacyclin in the news

Be alerted to news on Prostacyclin

News trends on Prostacyclin

Commentary

Blogs on Prostacyclin

Definitions

Definitions of Prostacyclin

Patient Resources / Community

Patient resources on Prostacyclin

Discussion groups on Prostacyclin

Patient Handouts on Prostacyclin

Directions to Hospitals Treating Prostacyclin

Risk calculators and risk factors for Prostacyclin

Healthcare Provider Resources

Symptoms of Prostacyclin

Causes & Risk Factors for Prostacyclin

Diagnostic studies for Prostacyclin

Treatment of Prostacyclin

Continuing Medical Education (CME)

CME Programs on Prostacyclin

International

Prostacyclin en Espanol

Prostacyclin en Francais

Business

Prostacyclin in the Marketplace

Patents on Prostacyclin

Experimental / Informatics

List of terms related to Prostacyclin

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Please Join in Editing This Page and Apply to be an Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Overview

Prostacyclin is a member of the family of lipid molecules known as eicosanoids. A synthetic form of prostacyclin, used as a medicine, is referred to as epoprostenol.

Production

It is produced in endothelial cells from prostaglandin H2 (PGH2) by the action of the enzyme prostacyclin synthase. Although prostacyclin is considered an independent mediator, it is called PGI2 (prostaglandin I2) in eicosanoid nomenclature, and is a member of the prostanoids (together with the prostaglandins and thromboxane).

The series-3 prostaglandin PGH3 also follows the prostacyclin synthase pathway, yielding another prostacyclin, PGI3.(Fischer, 1985)  The unqualified term 'prostacyclin' usually refers to PGI2. PGI2 is derived from the ω-6 arachidonic acid. PGI3 is derived from the ω-3 EPA.

Eicosanoid synthesis. (Prostacyclin near bottom center.)

Mode of action

Prostacyclin acts chiefly to prevent platelet formation and clumping involved in blood clotting. It is also an effective vasodilator. Prostacyclin's interactions in contrast to thromboxane, another eicosanoid, strongly suggest a mechanism of cardiovascular homeostasis between the two hormones in relation to vascular damage.

Pharmacology

Synthetic prostacyclin analogues (iloprost, cisaprost) are used intravenously, subcutaneously or by inhalation:

Its production is inhibited indirectly by NSAIDs, which inhibit the cyclooxygenase enzymes COX1 and COX2. These convert arachidonic acid to PGH2, the immediate precursor of prostacyclin.

References

  • Fischer S, Weber PC (1985). "Thromboxane (TX) A3 and prostaglandin (PG) I3 are formed in man after dietary eicosapentaenoic acid: identification and quantification by capillary gas chromatography-electron impact mass spectrometry". Biomed. Mass Spectrom. 12 (9): 470-6. PMID 2996649.

See also

Essential fatty acid

Cost Effectiveness of Prostacyclin

| group5 = Clinical Trials Involving Prostacyclin | list5 = Ongoing Trials on Prostacyclin at Clinical Trials.govTrial results on ProstacyclinClinical Trials on Prostacyclin at Google


| group6 = Guidelines / Policies / Government Resources (FDA/CDC) Regarding Prostacyclin | list6 = US National Guidelines Clearinghouse on ProstacyclinNICE Guidance on ProstacyclinNHS PRODIGY GuidanceFDA on ProstacyclinCDC on Prostacyclin


| group7 = Textbook Information on Prostacyclin | list7 = Books and Textbook Information on Prostacyclin


| group8 = Pharmacology Resources on Prostacyclin | list8 = AND (Dose)}} Dosing of ProstacyclinAND (drug interactions)}} Drug interactions with ProstacyclinAND (side effects)}} Side effects of ProstacyclinAND (Allergy)}} Allergic reactions to ProstacyclinAND (overdose)}} Overdose information on ProstacyclinAND (carcinogenicity)}} Carcinogenicity information on ProstacyclinAND (pregnancy)}} Prostacyclin in pregnancyAND (pharmacokinetics)}} Pharmacokinetics of Prostacyclin


| group9 = Genetics, Pharmacogenomics, and Proteinomics of Prostacyclin | list9 = AND (pharmacogenomics)}} Genetics of ProstacyclinAND (pharmacogenomics)}} Pharmacogenomics of ProstacyclinAND (proteomics)}} Proteomics of Prostacyclin


| group10 = Newstories on Prostacyclin | list10 = Prostacyclin in the newsBe alerted to news on ProstacyclinNews trends on Prostacyclin</small>


| group11 = Commentary on Prostacyclin | list11 = Blogs on Prostacyclin

| group12 = Patient Resources on Prostacyclin | list12 = Patient resources on ProstacyclinDiscussion groups on ProstacyclinPatient Handouts on ProstacyclinDirections to Hospitals Treating ProstacyclinRisk calculators and risk factors for Prostacyclin


| group13 = Healthcare Provider Resources on Prostacyclin | list13 = Symptoms of ProstacyclinCauses & Risk Factors for ProstacyclinDiagnostic studies for ProstacyclinTreatment of Prostacyclin

| group14 = Continuing Medical Education (CME) Programs on Prostacyclin | list14 = CME Programs on Prostacyclin

| group15 = International Resources on Prostacyclin | list15 = Prostacyclin en EspanolProstacyclin en Francais

| group16 = Business Resources on Prostacyclin | list16 = Prostacyclin in the MarketplacePatents on Prostacyclin

| group17 = Informatics Resources on Prostacyclin | list17 = List of terms related to Prostacyclin


}}

de:Prostacyclin


Navigation WikiDoc | WikiPatient | Up To Date Pages | Recently Edited Pages | Recently Added Pictures

Table of Contents In Alphabetical Order | By Individual Diseases | Signs and Symptoms | Physical Examination | Lab Tests | Drugs

Editor Tools Become an Editor | Editors Help Menu | Create a Page | Edit a Page | Upload a Picture or File | Printable version | Permanent link | Maintain Pages | What Pages Link Here
There is no pharmaceutical or device industry support for this site and we need your viewer supported Donations | Editorial Board | Governance | Licensing | Disclaimers | Avoid Plagiarism | Policies
Linked-in.jpg